Blood Advances in a Different Vein

Blood Advances in a Different Vein

Research from recent issues of Blood Advances

Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs

Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...

Lower Risk of GVHD With Parous Female Sibling Donors Than With Male Unrelated Donors

Donor’s sex and number of previous pregnancies are well established risk factors for graft-versus-host disease (GVHD) in hematopoietic cell transplantation (HCT), with male sibling...

Standardized MRD Assay for FLT3-ITD-Mutated AML Could Guide AML Therapy Decisions

In a report published in Blood Advances, researchers describe a standardized minimal residual disease (MRD) assay that can detect FLT3-ITD mutations in patients with...

DOACs Versus Warfarin in Patients With Cancer and Atrial Fibrillation

Newer direct oral anticoagulants (DOACs) offer an effective alternative to warfarin that does not require monitoring, but these agents are often not recommended in...

Investigating a WT1 Peptide Vaccine in Patients With Acute Myeloid Leukemia

In an open-label, phase II study, treatment with galinpepimut-S (GPS) – a vaccine targeting the Wilms tumor 1 (WT1) protein – was well tolerated...

Understanding Bone Disease and Fractures in Patients With MGUS

Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...

Previous Malignancy May Increase Risk of Subsequent Malignancy in Patients With Myeloma

A number of new treatments for patients with multiple myeloma (MM) have become available in recent years, enabling patients to live longer. Unfortunately, these...

HCT Outcomes in Patients With Autoimmune Diseases Vary With Location, Treatment Center Volume

Hematopoietic cell transplantation (HCT) has been evaluated as a treatment option for patients with autoimmune diseases (ADs) that respond poorly to conventional immunosuppressive treatments...

Patients With CLL Willing to Trade Treatment Efficacy for Reduced Costs and Adverse Events

Some patients living with chronic lymphocytic leukemia (CLL) are willing to accept drugs that are less effective in exchange for reduced adverse events (AEs)...

High Rates of Depression Resulting in Higher Health-Care Costs in Patients With Sickle Cell...

Depression is approximately five times more prevalent in patients with sickle cell disease (SCD) than in the general population, and it is significantly associated...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.